WTAP integrates inflammatory-oncogenic processes, driving NLRP3 activation in diabetic nephropathy, enabling epigenetic remodeling through TEX41 degradation in RCC, and defining molecular subtypes in lupus nephritis (Zhao et al., 2021b; Lan et al., 2022; Zhou et al., 2024). This evidence concerns the gene WTAP and diabetic kidney disease.